SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Novo Nordisk Reports Positive Phase 3 REDEFINE 9 CagriSema Results

Novo Nordisk said the trial evaluating CagriSema, an investigational treatment for adults with overweight or obesity, met its primary results positively.

NOVOB

Related stories